Apimeds Pharmaceuticals US, Inc. Cash Flow-to-Debt Ratio
Apimeds Pharmaceuticals US, Inc. cash flow-to-debt ratio. Apimeds Pharmaceuticals US, Inc. (APUS) has a Cash Flow-to-Debt Ratio of -0.15x as of March 2026, meaning its operating cash flow of $-2.14 Million could theoretically repay 0% of its total liabilities ($14.70 Million) in one year. See Apimeds Pharmaceuticals US, Inc. leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Apimeds Pharmaceuticals US, Inc. (2021–2025)
Cash flow-to-debt ratio of Apimeds Pharmaceuticals US, Inc. from 2021 to 2025. Historical debt coverage capacity for Apimeds Pharmaceuticals US, Inc. across 5 annual periods. See APUS net asset quality index to measure how much of total assets are equity-financed.
Apimeds Pharmaceuticals US, Inc. Cash Flow-to-Debt Ratio by Year (2021–2025)
Apimeds Pharmaceuticals US, Inc. cash flow-to-debt ratio by year from 2021 to 2025. Year-by-year debt coverage analysis for Apimeds Pharmaceuticals US, Inc.. For the full cash flow conversion analysis, see Apimeds Pharmaceuticals US, Inc. (APUS) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.82x | $-8.93 Million | $10.84 Million | ▼ -54.0% |
| 2024 | -0.53x | $-733.53K | $1.37 Million | ▲ +66.7% |
| 2023 | -1.61x | $-627.79K | $390.20K | ▼ -158.4% |
| 2022 | -0.62x | $-448.17K | $719.78K | ▲ +68.9% |
| 2021 | -2.00x | $-823.11K | $410.65K | — |